These agents include angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), mineralocorticoid-receptor antagonists, and direct renin inhibitors, all of which can ...

New small-molecule inhibitors are being developed as well; Basel-based Novartis received approval for Tekturna (aliskiren), a direct renin inhibitor, just last year. Aldosterone synthesis ...